HCW Biologics

HCW Biologics EBIT per Employee

The EBIT per Employee of HCW Biologics (HCWB) as of Nov 16, 2026 is -152,487.18 USD. In the previous year, EBIT per Employee was -656,031.23 USD — a change of -76.76% (higher).

EBIT per Employee

-152,487.18USD

YoY

-76.76%

Last updated:

EBIT per Employee of HCW Biologics is 2025 -152,487.18 USD. EBIT per Employee of HCW Biologics was 2024 -656,031.23 USD. It decreases by -76.76% higher compared to the previous year.

The HCW Biologics EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-167,392.59 USD
Jan 1, 2020
-132,375.57 USD
Jan 1, 2021
-303,814.41 USD
Jan 1, 2022
-342,699.50 USD
Jan 1, 2023
-584,480.91 USD
Jan 1, 2024
-656,031.23 USD
Jan 1, 2025
-152,487.18 USD
The HCW Biologics EBIT per Employee history
YEAREBIT per EmployeeYoY
-152,487.18USD-76.76%
-656,031.23USD+12.24%
-584,480.91USD+70.55%
-342,699.50USD+12.80%
-303,814.41USD+129.51%
-132,375.57USD-20.92%
-167,392.59USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HCW Biologics Stock analysis

What does HCW Biologics do? HCW Biologics Inc. generates revenue through the development and commercialization of novel immunotherapies targeting age-related diseases. The company's lead product candidates, HCW9218 and HCW9302, are being evaluated in clinical trials for conditions such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. HCW9218 focuses on eliminating senescent cells and reducing SASP factors, while HCW9302 aims to activate and expand regulatory T cells. The firm utilizes its TOBI discovery platform to create multi-functional fusion molecules with immunotherapeutic properties, targeting chronic inflammation linked to age-related health issues. The company's primary customers are pharmaceutical and biotechnology companies seeking innovative treatments for age-related conditions. HCW Biologics' focus on disrupting the connection between low-grade inflammation and diseases like cancer and neurodegenerative disorders positions it within the biopharmaceutical sector. The firm's clinical-stage products are developed to address unmet medical needs in the treatment of chronic inflammatory conditions associated with aging. HCW Biologics Inc. monetizes its research and development efforts through potential future sales of its immunotherapies once clinical trials demonstrate efficacy and safety. The company's TOBI platform enables the creation of novel fusion molecules, which form the basis for its pipeline of product candidates. By targeting multiple disease areas including cancer and cardiovascular diseases, the firm aims to capture market segments seeking advanced therapeutic solutions for age-related health challenges. HCW Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HCW Biologics stock

EBIT per Employee of HCW Biologics is -152,487.18 USD in 2025.

EBIT per Employee of HCW Biologics changed from -656,031.23 USD to -152,487.18 USD, representing a -76.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee HCW Biologics since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's HCW Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — HCW Biologics

All Key Metrics — HCW Biologics